Information Provided By:
Fly News Breaks for February 26, 2020
Feb 26, 2020 | 06:10 EDT
Piper Sandler analyst David Amsellem lowered the firm's price target on Jazz Pharmaceuticals to $129 from $142 and reiterates a Neutral rating on the shares. Sunosi is ramping, but only gradually, Amsellem tells investors in a post-earnings research note. He reduced his estimates to reflect Jazz's spending ramp in 2020.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ